Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma
Autore:
Wilson, AM; Orr, LC; Sims, EJ; Dempsey, OJ; Lipworth, BJ;
Indirizzi:
Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland Univ Dundee Dundee Scotland DD1 9SY gy Res Grp, Dundee DD1 9SY, Scotland
Titolo Testata:
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
fascicolo: 4, volume: 162, anno: 2000,
pagine: 1297 - 1301
SICI:
1073-449X(200010)162:4<1297:AEOMBV>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEUKOTRIENE RECEPTOR ANTAGONIST; BRONCHIAL RESPONSIVENESS; FLUTICASONE PROPIONATE; AIRWAY; BUDESONIDE; INFLAMMATION; MONTELUKAST; CETIRIZINE; CHALLENGE; PLACEBO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Lipworth, BJ Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland Univ Dundee Dundee Scotland DD1 9SY undee DD1 9SY, Scotland
Citazione:
A.M. Wilson et al., "Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma", AM J R CRIT, 162(4), 2000, pp. 1297-1301

Abstract

To compare the antiasthmatic efficacy of inflammatory mediator blockade versus topical corticosteroid therapy in patients with seasonal allergic rhinitis (SAR) and asthma, 14 patients were enrolled into a single-blind, double-dummy, placebo-controlled crossover study comparing 2 wk therapy of (1) 400 mu g orally inhaled budesonide plus 200 mu g intranasal budesonide (BUD)or (2) 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ). Beforeeach treatment period, patients received 7 to 10 d placebo washout. All treatments were given once daily in the morning. Throughout the study, patients recorded the following domiciliary measures: peak expiratory flow (PEF),rescue inhaler requirement, asthma symptoms, and daily activity score. Laboratory measurements were made at trough of adenosine monophosphate (AMP) bronchial challenge and exhaled nitric oxide (NO). Compared with pooled placebo (PL), there were significant (p < 0.05) improvements in all domiciliarymeasures with both treatments (mean PEF [L/min] PL: 463; BUD: 478; ML + CZ: 483). For geometric mean AMP PC20 (mg/ml), there was an improvement (p < 0.05), compared with PL (47), for ML + CZ (133) but not for BUD (51); whereas for NO (ppb) there was significant suppression with BUD (7.6) but not ML+ CZ (11.5) compared with PL (13.6). In conclusion, both combined mediatorblockade and combined topical corticosteroids are equally effective antiasthma therapy in patients with asthma and SAR.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/02/20 alle ore 14:42:10